• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessing plasminogen activation potential with global fibrinolytic assays.

作者信息

Urano Tetsumei, Suzuki Yuko

机构信息

Hamamatsu University School of Medicine-Medical Physiology Hamamatsu Shizuoka Japan.

出版信息

Res Pract Thromb Haemost. 2019 Dec 26;4(1):13-15. doi: 10.1002/rth2.12293. eCollection 2020 Jan.

DOI:10.1002/rth2.12293
PMID:31989079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6971321/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e36/6971321/7b185e469ed9/RTH2-4-13-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e36/6971321/7b185e469ed9/RTH2-4-13-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e36/6971321/7b185e469ed9/RTH2-4-13-g001.jpg

相似文献

1
Assessing plasminogen activation potential with global fibrinolytic assays.采用整体纤溶测定法评估纤溶酶原激活潜力。
Res Pract Thromb Haemost. 2019 Dec 26;4(1):13-15. doi: 10.1002/rth2.12293. eCollection 2020 Jan.
2
Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia.全球纤溶能力增加作为子痫前期激活纤溶的线索。
Blood Coagul Fibrinolysis. 2006 Jul;17(5):347-52. doi: 10.1097/01.mbc.0000233364.72863.a0.
3
Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.采用纤维蛋白和非纤维蛋白检测法测定人肿瘤组织及相邻正常组织中的纤溶酶原激活物含量。
Cancer Res. 1986 Apr;46(4 Pt 1):1788-94.
4
The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state.
Blood Coagul Fibrinolysis. 1992 Dec;3(6):789-93. doi: 10.1097/00001721-199212000-00013.
5
The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Jpn Heart J. 2004 Nov;45(6):977-87. doi: 10.1536/jhj.45.977.
6
Fibrinolytic response to trauma.
Surgery. 1984 Apr;95(4):473-8.
7
Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.解除肺栓塞中纤维蛋白溶解系统的制动：纤溶酶原激活和α2-抗纤溶酶失活的独特作用
Circulation. 2017 Mar 14;135(11):1011-1020. doi: 10.1161/CIRCULATIONAHA.116.024421. Epub 2016 Dec 27.
8
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
9
Plasma fibrinolytic profile in patients with brain tumors.
Thromb Haemost. 1991 Jan 23;65(1):15-9.
10
Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation.
Int J Dermatol. 1990 Nov;29(9):644-8. doi: 10.1111/j.1365-4362.1990.tb02587.x.

引用本文的文献

1
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.缺乏纤维蛋白溶解亢进可能解释了氨甲环酸在低增生性血小板减少症中无效。
Blood Adv. 2023 Mar 28;7(6):900-908. doi: 10.1182/bloodadvances.2022008255.
2
A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant.一个罕见的 MAST2 基因突变导致一个法国家族性不明原因血栓形成伴静脉血栓形成：Breizh MAST2 Arg89Gln 变异体。
PLoS Genet. 2021 Jan 19;17(1):e1009284. doi: 10.1371/journal.pgen.1009284. eCollection 2021 Jan.

本文引用的文献

1
Development and application of global assays of hyper- and hypofibrinolysis.高纤溶和低纤溶整体检测方法的开发与应用。
Res Pract Thromb Haemost. 2019 Nov 6;4(1):46-53. doi: 10.1002/rth2.12275. eCollection 2020 Jan.
2
Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.认识到纤溶酶原激活物抑制剂1是纤维蛋白溶解的主要调节因子。
Curr Drug Targets. 2019;20(16):1695-1701. doi: 10.2174/1389450120666190715102510.
3
Regulation of plasminogen activation on cell surfaces and fibrin.细胞表面和纤维蛋白上纤溶酶原激活的调节
J Thromb Haemost. 2018 May 20;16(8):1487-97. doi: 10.1111/jth.14157.
4
Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerisation.纤溶酶原激活物抑制剂1第5B链中一个高度保守的甘氨酸残基发生突变会导致聚合反应。
Thromb Haemost. 2017 May 3;117(5):860-869. doi: 10.1160/TH16-07-0572. Epub 2017 Feb 23.
5
Disseminated intravascular coagulation.弥散性血管内凝血。
Nat Rev Dis Primers. 2016 Jun 2;2:16037. doi: 10.1038/nrdp.2016.37.
6
Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans.危及生命的出血和伤口愈合延长是人类完全缺乏纤溶酶原激活物抑制剂-1所表现出的显著表型。
J Thromb Haemost. 2011 Jun;9(6):1200-6. doi: 10.1111/j.1538-7836.2011.04288.x.
7
New insights into the molecular mechanisms of the fibrinolytic system.纤溶系统分子机制的新见解。
J Thromb Haemost. 2009 Jan;7(1):4-13. doi: 10.1111/j.1538-7836.2008.03220.x. Epub 2008 Nov 8.
8
Discovery of alpha2-plasmin inhibitor and its congenital deficiency.α2-纤溶酶抑制剂的发现及其先天性缺乏症。
J Thromb Haemost. 2005 Apr;3(4):623-31. doi: 10.1111/j.1538-7836.2004.01055.x.
9
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.纤溶酶原激活物抑制剂-1、炎症、肥胖、胰岛素抵抗与血管风险
J Thromb Haemost. 2003 Jul;1(7):1575-9. doi: 10.1046/j.1538-7836.2003.00279.x.
10
The expression of exercise-induced tPA activity in blood is regulated by the basal level of PAI-1.
Thromb Haemost. 2001 Apr;85(4):751-2.